Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Profile of Infective Endocarditis: At a Tertiary Care Referral Centre.

R M, V R, Nambi PS, Ramakrishnan B, Gopalakrishnan R, Sathyamurthy.

J Assoc Physicians India. 2018 Jun;66(6):60-65.

PMID:
31331138
2.

Carbapenem-resistant enterobacteriaceae screening: A core infection control measure for critical care unit in India?

Ramanathan YV, Venkatasubramanian R, Nambi PS, Ramabathiran M, Venkataraman R, Thirunarayan MA, Samundeeswari P, Ramakrishnan N.

Indian J Med Microbiol. 2018 Oct-Dec;36(4):572-576. doi: 10.4103/ijmm.IJMM_18_437.

PMID:
30880709
3.

Glycyrrhizic acid renders robust neuroprotection in rodent model of vascular dementia by controlling oxidative stress and curtailing cytochrome-c release.

Sathyamoorthy Y, Kaliappan K, Nambi P, Radhakrishnan R.

Nutr Neurosci. 2019 Feb 22:1-16. doi: 10.1080/1028415X.2019.1580935. [Epub ahead of print]

PMID:
30794076
4.

Can urinary histoplasma antigen test improve the diagnosis of histoplasmosis in a tuberculosis endemic region?

Bansal N, Sethuraman N, Gopalakrishnan R, Ramasubramanian V, Kumar D S, Nambi P S, Chakrabarti A.

Mycoses. 2019 Jun;62(6):502-507. doi: 10.1111/myc.12902. Epub 2019 Mar 21.

PMID:
30734964
5.

Melioidosis mimicking tuberculous vertebral osteitis: Case report and review of literature.

Pande A, Nambi PS, Pandian S, Subramanian S, Ghosh S.

Neurol India. 2018 Jul-Aug;66(4):1100-1105. doi: 10.4103/0028-3886.236976. Review.

6.

Experience with β-D-Glucan Assay in the Management of Critically ill Patients with High Risk of Invasive Candidiasis: An Observational Study.

Bansal N, Gopalakrishnan R, Sethuraman N, Ramakrishnan N, Nambi PS, Kumar DS, Madhumitha R, Thirunarayan MA, Ramasubramanian V.

Indian J Crit Care Med. 2018 May;22(5):364-368. doi: 10.4103/ijccm.IJCCM_4_18.

7.

Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India.

Bansal N, Sukhwani KS, Kumar D S, Nambi PS, Gopalakrishnan R, Ramasubramanian V.

Infect Dis (Lond). 2018 May;50(5):391-394. doi: 10.1080/23744235.2017.1410284. Epub 2017 Nov 30. No abstract available.

PMID:
29188735
8.

Listeria in Adults - Truly Rare or Rarely Diagnosed in India?

Rajalakshmi A, Gopalakrishnan R, Nambi PS, Rao PV, Ramasubramanian V.

J Assoc Physicians India. 2017 Jul;65(7):106-108.

PMID:
28792179
9.

A Study of 24 Patients with Colistin-Resistant Gram-negative Isolates in a Tertiary Care Hospital in South India.

Arjun R, Gopalakrishnan R, Nambi PS, Kumar DS, Madhumitha R, Ramasubramanian V.

Indian J Crit Care Med. 2017 May;21(5):317-321. doi: 10.4103/ijccm.IJCCM_454_16.

10.

Temporal fine structure mediated recognition of speech in the presence of multitalker babble.

Nambi PM, Mahajan Y, Francis N, Bhat JS.

J Acoust Soc Am. 2016 Oct;140(4):EL296.

PMID:
27794309
11.

Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.

Prabhudesai S, Kanjani A, Nambi PS, Gnanasambandam S, Ramachandran B.

Pediatr Infect Dis J. 2016 May;35(5):517-8. doi: 10.1097/INF.0000000000000958.

PMID:
27074655
12.

Histoplasmosis in India: truly uncommon or uncommonly recognised?

Gopalakrishnan R, Nambi PS, Ramasubramanian V, Abdul Ghafur K, Parameswaran A.

J Assoc Physicians India. 2012 Oct;60:25-8.

PMID:
23777021
13.

Antimicrobial susceptibility of Salmonella enterica serovars in a tertiary care hospital in southern India.

Choudhary A, Gopalakrishnan R, Nambi PS, Ramasubramanian V, Ghafur KA, Thirunarayan MA.

Indian J Med Res. 2013 Apr;137(4):800-2.

14.

Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.

Wooten JS, Nambi P, Gillard BK, Pownall HJ, Coraza I, Scott LW, Nambi V, Ballantyne CM, Balasubramanyam A.

Med Sci Sports Exerc. 2013 Jun;45(6):1043-50. doi: 10.1249/MSS.0b013e3182843961.

15.

Clinical, epidemiological, and microbiological profile of patients with vancomycin-resistant enterococci from a tertiary care hospital.

Vidyalakshmi P, Gopalakrishnan R, Ramasubramanian V, Ghafur KA, Nambi PS, Thirunarayana M.

J Glob Infect Dis. 2012 Apr;4(2):137-8. doi: 10.4103/0974-777X.96784. No abstract available.

16.

Non-contrast computed tomography is comparable to contrast-enhanced computed tomography for aortic volume analysis after endovascular abdominal aortic aneurysm repair.

Nambi P, Sengupta R, Krajcer Z, Muthupillai R, Strickman N, Cheong BY.

Eur J Vasc Endovasc Surg. 2011 Apr;41(4):460-6. doi: 10.1016/j.ejvs.2010.11.027. Epub 2010 Dec 31.

17.

The impact of diabetes process and outcome quality measures on overall survival in patients with co-morbid colorectal cancer.

Chiao EY, Nambi PV, Naik AD.

J Cancer Surviv. 2010 Dec;4(4):381-7. doi: 10.1007/s11764-010-0141-y. Epub 2010 Aug 19. Erratum in: J Cancer Surviv. 2011 Mar;5(1):113.

18.

Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.

Ullrich JW, Morris R, Bernotas RC, Travins JM, Jetter J, Unwalla R, Quinet E, Nambi P, Feingold I, Huselton C, Enroth C, Wilhelmsson A, Goos-Nilsson A, Wrobel J.

Bioorg Med Chem Lett. 2010 May 1;20(9):2903-7. doi: 10.1016/j.bmcl.2010.03.031. Epub 2010 Mar 9.

PMID:
20382019
19.

1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.

Travins JM, Bernotas RC, Kaufman DH, Quinet E, Nambi P, Feingold I, Huselton C, Wilhelmsson A, Goos-Nilsson A, Wrobel J.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):526-30. doi: 10.1016/j.bmcl.2009.11.099. Epub 2009 Nov 23.

PMID:
20006495
20.

3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.

Singhaus RR, Bernotas RC, Steffan R, Matelan E, Quinet E, Nambi P, Feingold I, Huselton C, Wilhelmsson A, Goos-Nilsson A, Wrobel J.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):521-5. doi: 10.1016/j.bmcl.2009.11.098. Epub 2009 Nov 23.

PMID:
20005711
21.

Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.

Hu B, Bernotas R, Unwalla R, Collini M, Quinet E, Feingold I, Goos-Nilsson A, Wilhelmsson A, Nambi P, Evans M, Wrobel J.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):689-93. doi: 10.1016/j.bmcl.2009.11.062. Epub 2009 Dec 3.

PMID:
19962892
22.

4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.

Bernotas RC, Singhaus RR, Kaufman DH, Travins JM, Ullrich JW, Unwalla R, Quinet E, Evans M, Nambi P, Olland A, Kauppi B, Wilhelmsson A, Goos-Nilsson A, Wrobel J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):209-12. doi: 10.1016/j.bmcl.2009.10.132. Epub 2009 Oct 31.

PMID:
19932617
23.

4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.

Bernotas RC, Kaufman DH, Singhaus RR, Ullrich J, Unwalla R, Quinet E, Nambi P, Wilhelmsson A, Goos-Nilsson A, Wrobel J.

Bioorg Med Chem. 2009 Dec 1;17(23):8086-92. doi: 10.1016/j.bmc.2009.10.001. Epub 2009 Oct 4.

PMID:
19853462
24.

Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.

Hu B, Unwalla R, Collini M, Quinet E, Feingold I, Goos-Nilsson A, Wihelmsson A, Nambi P, Wrobel J.

Bioorg Med Chem. 2009 May 15;17(10):3519-27. doi: 10.1016/j.bmc.2009.04.012. Epub 2009 Apr 12.

PMID:
19394832
25.

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W, Hartman HB, Evans MJ, Gardell SJ, DiBlasio-Smith E, Mounts WM, LaVallie ER, Wrobel J, Nambi P, Vlasuk GP.

J Lipid Res. 2009 Dec;50(12):2358-70. doi: 10.1194/jlr.M900037-JLR200. Epub 2009 Mar 24.

26.

Biarylether amide quinolines as liver X receptor agonists.

Bernotas RC, Singhaus RR, Kaufman DH, Ullrich J, Fletcher H 3rd, Quinet E, Nambi P, Unwalla R, Wilhelmsson A, Goos-Nilsson A, Farnegardh M, Wrobel J.

Bioorg Med Chem. 2009 Feb 15;17(4):1663-70. doi: 10.1016/j.bmc.2008.12.048. Epub 2008 Dec 27.

PMID:
19162487
27.

Multislice computed tomography of a repaired anomalous left coronary artery arising from the pulmonary artery.

Nambi P, Sengupta R, Cheong BY.

Tex Heart Inst J. 2008;35(4):485-6. No abstract available.

28.

Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.

Wrobel J, Steffan R, Bowen SM, Magolda R, Matelan E, Unwalla R, Basso M, Clerin V, Gardell SJ, Nambi P, Quinet E, Reminick JI, Vlasuk GP, Wang S, Feingold I, Huselton C, Bonn T, Farnegardh M, Hansson T, Nilsson AG, Wilhelmsson A, Zamaratski E, Evans MJ.

J Med Chem. 2008 Nov 27;51(22):7161-8. doi: 10.1021/jm800799q.

PMID:
18973288
29.

Previous left main coronary artery dissection: detected upon multislice computed tomography.

Nambi P, Sengupta R, Cheong BY.

Tex Heart Inst J. 2008;35(3):365-6. No abstract available.

30.

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.

DiBlasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, Basso MD, Chen L, Feingold I, Halpern AR, Liu QY, Nambi P, Savio D, Wang S, Mounts WM, Isler JA, Slager AM, Burczynski ME, Dorner AJ, LaVallie ER.

J Transl Med. 2008 Oct 16;6:59. doi: 10.1186/1479-5876-6-59.

31.

Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.

Hu B, Quinet E, Unwalla R, Collini M, Jetter J, Dooley R, Andraka D, Nogle L, Savio D, Halpern A, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):54-9. Epub 2007 Nov 9.

PMID:
18023179
32.

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P.

Br J Pharmacol. 2007 Jun;151(4):450-6. Epub 2007 Apr 10.

33.

Adipocyte fatty acid-binding protein (aP2), a newly identified LXR target gene, is induced by LXR agonists in human THP-1 cells.

Liu QY, Quinet E, Nambi P.

Mol Cell Biochem. 2007 Aug;302(1-2):203-13. Epub 2007 Mar 30.

PMID:
17396233
34.

Further modification on phenyl acetic acid based quinolines as liver X receptor modulators.

Hu B, Jetter J, Kaufman D, Singhaus R, Bernotas R, Unwalla R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Liu QY, Feingold I, Huselton C, Azam F, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J.

Bioorg Med Chem. 2007 May 15;15(10):3321-33. Epub 2007 Mar 12.

PMID:
17391964
35.

Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.

Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Resmini C, Liu QY, Feingold I, Huselton C, Azam F, Farnegardh M, Enroth C, Bonn T, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J.

J Med Chem. 2006 Oct 19;49(21):6151-4.

PMID:
17034119
36.

Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.

Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA.

J Thromb Haemost. 2006 Dec;4(12):2710-5. Epub 2006 Oct 2.

37.

Identification and characterization of triosephosphate isomerase that specifically interacts with the integrin alphaIIb cytoplasmic domain.

Liu QY, Corjay M, Feuerstein GZ, Nambi P.

Biochem Pharmacol. 2006 Aug 28;72(5):551-7. Epub 2006 Jul 20.

PMID:
16859644
38.

Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.

Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson JA, Basso MD, Nambi P.

Mol Pharmacol. 2006 Oct;70(4):1340-9. Epub 2006 Jul 6.

PMID:
16825483
39.

The occurrence of nymphal stage of Linguatula serrata in water buffaloes (Bubalus bubalis): nymphal morphometry and lymph node pathology.

Sivakumar P, Sankar M, Nambi PA, Praveena PE, Singh N.

J Vet Med A Physiol Pathol Clin Med. 2005 Dec;52(10):506-9.

PMID:
16300658
40.

Fasciola gigantica cathepsin-L cysteine proteinase in the detection of early experimental fasciolosis in ruminants.

Yadav SC, Saini M, Raina OK, Nambi PA, Jadav K, Sriveny D.

Parasitol Res. 2005 Dec;97(6):527-34. Epub 2005 Oct 13.

PMID:
16222528
41.

Vaccination of buffaloes with Fasciola gigantica recombinant fatty acid binding protein.

Nambi PA, Yadav SC, Raina OK, Sriveny D, Saini M.

Parasitol Res. 2005 Sep;97(2):129-35. Epub 2005 Jun 29.

PMID:
15986249
42.

Sirolimus upregulates aP2 expression in human monocytes and macrophages.

Liu QY, Nambi P.

Transplant Proc. 2004 Dec;36(10):3229-31.

PMID:
15686734
43.

Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.

Quinet EM, Savio DA, Halpern AR, Chen L, Miller CP, Nambi P.

J Lipid Res. 2004 Oct;45(10):1929-42. Epub 2004 Aug 1.

44.

Okadaic acid stimulates caspase-like activities and induces apoptosis of cultured rat mesangial cells.

Parameswaran N, Spielman WS, Brooks DP, Nambi P.

Mol Cell Biochem. 2004 May;260(1-2):7-11.

PMID:
15228080
45.

G protein-coupled receptors in drug discovery.

Nambi P, Aiyar N.

Assay Drug Dev Technol. 2003 Apr;1(2):305-10. Review.

PMID:
15090195
46.

Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice.

Basso MD, Nambi P, Adelman SJ.

Transplant Proc. 2003 Dec;35(8):3136-8.

PMID:
14697997
47.

Molecular cloning and pharmacological characterization of bovine calcitonin receptor-like receptor from bovine aortic endothelial cells.

Aiyar N, Disa J, Ao Z, Xu D, Surya A, Pillarisetti K, Parameswaran N, Gupta SK, Douglas SA, Nambi P.

Biochem Pharmacol. 2002 Jun 1;63(11):1949-59.

PMID:
12093471
48.
49.

Endothelin and heart failure.

Nambi P, Clozel M, Feuerstein G.

Heart Fail Rev. 2001 Dec;6(4):335-40. Review.

PMID:
11447308
50.

Supplemental Content

Support Center